NMRA Neumora Therapeutics, Inc.

Nasdaq neumoratx.com


$ 1.73 $ -0.07 (-4.17 %)    

Wednesday, 22-Oct-2025 11:32:41 EDT
QQQ $ 605.48 $ -5.35 (-0.88 %)
DIA $ 467.79 $ -1.43 (-0.3 %)
SPY $ 668.19 $ -3.73 (-0.56 %)
TLT $ 91.96 $ -0.03 (-0.03 %)
GLD $ 370.71 $ -2.13 (-0.57 %)
$ 1.8
$ 1.80
$ 1.72 x 1,592
$ 1.73 x 339
$ 1.72 - $ 1.78
$ 0.61 - $ 14.09
427,431
na
291.5M
$ 2.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-downgrades-neumora-therapeutics-to-underweight

JP Morgan analyst Tessa Romero downgrades Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Underweight.

 mizuho-maintains-outperform-on-neumora-therapeutics-raises-price-target-to-5

Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and raises the price target ...

 neumora-therapeutics-begins-phase-1-clinical-trial-of-nmra-861-a-selective-m4-positive-allosteric-modulator-for-schizophrenia

NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profileNo convulsions observed...

 on-may-14-neumora-therapeutics-received-nasdaq-non-compliance-notice

-SEC Filing

 needham-reiterates-buy-on-neumora-therapeutics-maintains-5-price-target

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $5 price target.

 neumora-therapeutics-q1-eps-042-misses-038-estimate

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate o...

 needham-reiterates-buy-on-neumora-therapeutics-maintains-5-price-target

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $5 price target.

 b-of-a-securities-downgrades-neumora-therapeutics-to-underperform-lowers-price-target-to-1

B of A Securities analyst Geoff Meacham downgrades Neumora Therapeutics (NASDAQ:NMRA) from Buy to Underperform and lowers th...

 guggenheim-downgrades-neumora-therapeutics-to-neutral

Guggenheim analyst Yatin Suneja downgrades Neumora Therapeutics (NASDAQ:NMRA) from Buy to Neutral.

 stifel-downgrades-neumora-therapeutics-to-hold-lowers-price-target-to-2

Stifel analyst Paul Matteis downgrades Neumora Therapeutics (NASDAQ:NMRA) from Buy to Hold and lowers the price target from ...

 johnson--johnson-stops-late-stage-depression-study-over-insufficient-efficacy

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato...

 hc-wainwright--co-reiterates-buy-on-neumora-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $18 pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION